Cronos GroupSTU:7CI -1.04%85 PEG Ratio is 0.90 as of Jul. 05, 2026, which is 25% above its 10-year median of 0.72. GuruFocus rates STU:7CI with a GF Score™ of 85/100 and a GF Value™ of €3.09 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 348 Drug Manufacturers companies, Cronos Group ranks better than 71.55% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Cronos Group's PEG Ratio or its related term are showing as below:
STU:7CI'
s PEG Ratio Range Over the Past 10 Years
Min: 0.63 Med: 0.72 Max: 0.92
Current: 0.92
During the past 12 years, Cronos Group's highest PEG Ratio was 0.92. The lowest was 0.63. And the median was 0.72.
STU:7CI's PEG Ratio is ranked better than 71.55% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.7
vs STU:7CI: 0.92
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Cronos Group (STU:7CI) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Cronos Group PEG Ratio Related Terms
Cronos Group PEG Ratio Historical Data
* Premium members only.
The historical data trend for Cronos Group's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Cronos Group's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Cronos Group (STU:7CI) has a PEG Ratio of 0.90 as of Jul. 05, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Cronos Group and its competitors. This is 25% above median its historical median of 0.72. Over the past decade, Cronos Group's PEG Ratio has ranged from 0.63 to 0.92. According to the industry distribution chart, Cronos Group ranks #99 out of 348 companies in the Drug Manufacturers industry, placing it in the top 28.4%.
Is Cronos Group's PEG Ratio too high?
Cronos Group's current PEG Ratio of 0.90 is 25% above median its 10-year median of 0.72. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 0.92. The Drug Manufacturers industry median PEG Ratio is 1.70. Cronos Group's value of 0.90 is 47.1% below this industry median. Based on the distribution chart, Cronos Group ranks #99 out of 348 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cronos Group has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #99 out of 348 companies for PEG Ratio. This puts Cronos Group in the upper half of its industry. The industry median PEG Ratio is 1.70. Cronos Group's value of 0.90 is 47.1% below this benchmark. Historically, Cronos Group's own PEG Ratio has ranged from 0.63 to 0.92 over the past decade. While the company's 10-year median is 0.72 vs. the industry median of 1.70, Cronos Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.70, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current PEG Ratio of 0.90 is 47.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current PEG Ratio is 0.90, which is 25% above median its own 10-year median of 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (STU:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.09, compared to a current price of €2.47 — trading 20.2% below its estimated fair value. The current PEG Ratio is 0.90, which is 25% above median its 10-year median of 0.72 and 47.1% below the Drug Manufacturers industry median of 1.70. Cronos Group's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Cronos Group (STU:7CI), the current PEG Ratio is 0.90 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (STU:7CI) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of €2.47 is trading 20.2% below its estimated GF Value™ of €3.09.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for STU:7CI:
PEG Ratio: 0.90 (25% above median its 10-year median of 0.72)
GF Value™: €3.09 vs. price of €2.47 (20.2% below fair value)
Industry Position: 47.1% below the Drug Manufacturers median (#99 of 348)
No single metric tells the full story. See the STU:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
85GF Score
Get the complete analysis for STU:7CI
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7CI has been successfully added to your 
